Whole Network Most Recent TOP10 Gene Therapy Microbiology Nanomedicine Stem Cells

 

TYKERB®: GlaxoSmithKline's Breast Cancer Drug, Approved by the FDA

Filed in archive Drugs, Vaccines and Therapeutics by ruth on March 16, 2007

TYKERB®: GlaxoSmithKline's Breast Cancer Drug, Approved by the FDA
The first targeted, once-daily oral treatment option for the following patient population:
  • patients with advanced or metastaticlinks breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab
...GlaxoSmithKline's breast cancer drug TYKERB® (lapatinib) has recently been approved by the US FDA in combination with Xeloda® (capecitabine) for the treatment of advanced metastatic breast cancer in the specified patient population.

The said FDA approval represents more than 16 years of research, including more than 60 clinical trials and investigator-initiated collaborative research studies.

According to Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GSK:

"Tykerb is a significant breakthrough for women with advanced HER2 (ErbB2) positive breast cancer. The data clearly show that this small molecule, oral, targeted agent, in combination with capecitabine, is effective for women whose disease has progressed on previous therapies, including anthracyclines, taxanes and trastuzumab.

The approval of TYKERB demonstrates our R&D organization's strong commitment to the discovery and development of novel cancer treatments. We are dedicated to the further study and development of Tykerb in a variety of settings including adjuvant breast cancer as well as in other solid tumor types."


Granted priority review by the FDA in November 2006, TYKERB® is designed to interfere with discrete cellular processes or disease mechanisms prevalent in cancer - it inhibits two validated targets in oncology, the kinase components of the EGFR (ErbB1) and HER2 (ErbB2) receptors, commonly associated with cancer cell proliferation and tumor growth.

Within two weeks of this approval, TYKERB® will be available in the United States.

Read the full report.


Advertisement


Permalink: TYKERB®: GlaxoSmithKline's Breast Cancer Drug, Approved by the FDA
Tags: Tykerb  breast  cancer  breast  cancer  drug 

Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/58310



Advertisement


Advertisement


CW ToolbarInstall
RSSrss   | See all blog subscribe options
Googlegoogle   |   What is RSS?
Yahoo!yahoo
AddthisAddThis Feed Button
BloglinesBloglines
Newsletter
Advertisement - Book yours here.

Use our search feature to look for other interesting posts

Just this blog Whole network
Advertisement -
Book yours here..


 
Advertisement
Book yours here.



  • Testimonials

  • 'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

    'I subscribe to your blog and have been enjoying your posts and perspective.'
  • Other blogs in the same channel in the Creative Weblogging Network

Advertisement -
Book yours here..






Advertisement - Book yours here..
 
Tagcloud: Biotech Hubs and Facilities Biotech/Science Blogs Corporate and Industrial News Diagnostics, Methodologies and Instrumentation Drugs, Vaccines and Therapeutics Energy, Environment and Ecology Food and Agriculture Gene Therapy Genomics, Proteomics and Bioinformatics Meetings and Other Events Microbiology Nanomedicine Other Biotechnology News Patents and Intellectual Property Rights Sponsored Post Stem Cells